NIH
PubMed Redesign
The NLM® has implemented the redesign of the PubMed interface. The previous version is no longer available. According to the NLM®, the interface was simplified to make it easier to use while promoting scientific discovery. Please note that search processing, including Automatic Term Mapping, has not changed. For more information about the changes, please see:
http://www.nlm.nih.gov/pubs/techbull/so09/so09_pm_redesign.html and
http://www.nlm.nih.gov/pubs/techbull/so09/so09_pm_now_redesign.html
For assistance using PubMed, please contact Lister Hill reference:
IM Chat or email https://www.uab.edu/lister/qpask
Phone 934-4821
What a PI needs to know about reporting requirements for a stimulus (ARRA) award
This is an update from June 16, 2009 about reporting requirements for a stimulus (ARRA) award.
- Stimulus funding comes with additional, NEW reporting responsibilities for the PI.
- ARRA awards will be characterized by OMB as “high-risk” and are more likely to be audited.
- NON-COMPLIANCE WITH THESE REPORTING REQUIREMENTS MAY RESULT IN LOSS OF FUNDING.
- Reporting obligations may vary by funding agency, so READ your award notice carefully.
- ADHERE to quarterly reporting DEADLINES. First post-award reports will be due October 10, 2009. Subsequent reports will be due no later than 10 calendar days after the end of each calendar quarter, e.g., January 10, 2010, April 10, 2010, July 10, 2010, etc. For awards funded prior to July 10, 2009, the October 10, 2009 report should provide cumulative data from the start date
REPORTS MUST INCLUDE:
- Financial data: funds received, funds expended, and funds obligated.
- A narrative progress report that includes: the name of the project, a description of activity during the quarter, an estimate of the completion status of the project, an estimate of the number of jobs created and retained, and additional reporting requirements for infrastructure grants.
- Reports MUST INCLUDE the same information as above for sub-awards of more than $25,000, therefore this information must be collected from sub-award recipients prior to the quarterly deadline.
- Reports will be submitted via an OMB website (www.federalreporting.gov – not yet active), although it is not clear who will be submitting reports, the PI or the institution.
- ALL DOCUMENTATION and supporting records for financial and progress reports must be RETAINED for audit and inspection purposes for 7 years AFTER the award end date. We are exploring central storage options to accommodate such records.
What a PI needs to know about spending stimulus funding
- ARRA funds will be accounted for separately from non-ARRA funds, even if both are for the same project.
- Spend ARRA money quickly – funds not spent within 12 months may be reallocated by the funding agency.
- Spend ARRA money APPROPRIATELY - ALLOWABLE costs incurred on a specific ARRA award MUST be charged to the project account for that ARRA award.
- ARRA funds may NOT be carried over to any other project, but a 1-year no-cost extension can be requested for ARRA-funded projects.
- Funds from regular grants may NOT be carried over to ARRA awards.
Additional guidance will be provided as new information from OMB becomes available. Questions…email stimulus@uab.edu .
Four things you need to know about Clinical and Translational Science
1. What is Clinical and Translational Science? In a nutshell, Clinical and Translational Science (CTS) is the process of moving scientific discoveries from laboratories to actual clinical practices in a physician’s office that benefit a patient. Some refer to the process as the “bench to bedside” approach. The goal of CTS is to bridge what some biomedical researchers are calling the Valley of Death. Despite many scientific discoveries being made each year in the US about the causes of disease and disability, there is problem getting this information translated into drugs, medical treatment and clinical procedures for patients and communities needing health care.
2. The Different Types of CTS. There are three different types of CTS, commonly referred to as the 3Ts. The first is T1 (or Translation 1) which refers to the transformation of evidence from basic science research into practical, clinical procedures or methods that can be used to treat patients. Again, this is the “bench to bedside” approach. Next is T2 research which is a refinement of T1 research to determine what of the clinical procedures or methods work best for which patients in what situations. T3 research takes the translational one step further to indentify that best ways to implement the new clinical knowledge throughout the entire health care system so that all patients can benefit from the new medical treatments. T3 research is also known as practice-based research.
3. The Road Map. The NIH Roadmap is the strategic plan used by the National Institutes of Health (NIH) to fund and guide biomedical research in the United States. The NIH recognizes that many issues need to be addressed to improve biomedical research in the US so the roadmap includes three different initiatives. The first is the New Pathways to Discovery which funds research that will improve our understanding of the human body and complex biological systems. The next is Research Teams of the Future which focuses on improving how researchers work and collaborate with each other on scientific discoveries. The third and final is Re-engineering the Clinical Research Enterprise which aims to speed up and improve the transformation of scientific discoveries to real-life medical treatments byre-vitalizing research infrastructure in the US.
4. The Clinical and Translational Science Awards (CTSAs). Since 2006, the NIH has funded 38 different CTSA academic research centers throughout the US. Institutions interested in establishing their own CTS research center apply for funding from the NIH through the CTSA funding mechanism. The purpose of these research centers is to conduct CTS research, train new researchers in CTS methods and improve the way in which CTS is conducted. In May 2008, UAB received CTSA funding from the NIH and established the UAB Center for Clinical and Translational Science.
